Atara Biotherapeutics, Inc.

NasdaqGS:ATRA Stock Report

Market Cap: US$55.0m

Atara Biotherapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:ATRA Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
16 May 25SellUS$22,156Anhco NguyenIndividual3,276US$6.76
16 May 25SellUS$15,000Yanina Grant-HuertaIndividual2,218US$6.76
16 May 25BuyUS$5,145,016Panacea Venture Management Co., Ltd.Company780,665US$6.61
03 Mar 25SellUS$7,410Jill HenrichIndividual1,059US$7.00
03 Mar 25SellUS$8,473Eric HyllengrenIndividual1,211US$7.00
03 Mar 25SellUS$23,307Anhco NguyenIndividual3,331US$7.00
18 Nov 24SellUS$15,274Eric HyllengrenIndividual1,364US$11.20
18 Nov 24SellUS$11,198Jill HenrichIndividual1,000US$11.20
18 Nov 24SellUS$18,633Anhco NguyenIndividual1,664US$11.20
16 Aug 24SellUS$6,384Jill HenrichIndividual963US$6.63
16 Aug 24SellUS$7,677K. MuruganIndividual1,158US$6.63
16 Aug 24SellUS$7,093Eric HyllengrenIndividual1,070US$6.63
16 Aug 24SellUS$12,072Anhco NguyenIndividual1,821US$6.63
16 Aug 24SellUS$20,139Pascal TouchonIndividual3,038US$6.63

Insider Trading Volume

Insider Buying: ATRA insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of ATRA?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders174,1232.92%
Hedge Funds1,014,88417%
General Public1,160,47919.5%
VC/PE Firms1,330,66522.3%
Institutions2,281,24038.3%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 23.8%.

Top Shareholders

Top 25 shareholders own 79.07% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
22.3%
Panacea Venture Management Co., Ltd.
1,330,665US$12.3m142%22.29%
20.3%
Adiumentum Capital Management
1,209,395US$11.2m6.67%no data
9.61%
EcoR1 Capital, LLC
573,183US$5.3m7.71%0.25%
7.41%
Redmile Group, LLC
441,701US$4.1m0%0.29%
3.2%
The Vanguard Group, Inc.
190,761US$1.8m6.7%no data
3.14%
Bank of America Corporation, Asset Management Arm
187,287US$1.7m-8.71%no data
1.93%
Acadian Asset Management LLC
115,111US$1.1m-7.52%no data
1.58%
Vestal Point Capital, LP
94,085US$868.4k-24.7%0.06%
1.34%
Staley Capital Advisers, Inc.
80,000US$738.4k60%0.03%
1.26%
Tang Capital Management, LLC
75,196US$694.1k0%0.03%
1.02%
BlackRock, Inc.
60,798US$561.2k0%no data
0.98%
Geode Capital Management, LLC
58,679US$541.6k7.19%no data
0.69%
Susquehanna International Group, LLP, Asset Management Arm
41,014US$378.6k0%no data
0.64%
Pascal Touchon
38,392US$354.4k0%no data
0.42%
State Street Global Advisors, Inc.
25,253US$233.1k0%no data
0.42%
Carol Gallagher
25,184US$232.4k31.3%no data
0.41%
UBS Asset Management AG
24,334US$224.6k2,820%no data
0.4%
Anhco Nguyen
23,656US$218.3k44%no data
0.37%
Birchview Capital, LP
22,000US$203.1k0%0.2%
0.33%
GSA Capital Partners LLP
19,385US$178.9k0%0.02%
0.29%
Renaissance Technologies LLC
17,436US$160.9k-74%no data
0.29%
FMR LLC
17,157US$158.4k-35.7%no data
0.25%
K. Murugan
14,738US$136.0k35.7%no data
0.24%
William Heiden
14,360US$132.5k71.8%no data
0.23%
Bridgeway Capital Management, LLC
14,000US$129.2k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/13 01:14
End of Day Share Price 2025/07/11 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Atara Biotherapeutics, Inc. is covered by 16 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John NewmanCanaccord Genuity
Yigal NochomovitzCitigroup Inc
Michael KingCitizens JMP Securities, LLC